Polatuzumab Vedotin Plus Bendamustine with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study

Sehn, Laurie H.; Matasar, Matthew J.; Flowers, Christopher R.; Kamdar, Manali; McMillan, Andrew; Hertzberg, Mark; Assouline, Sarit; Kim, Tae Min; Kim, Won Seog; Özcan, Muhıt; Croft, Brandon; Hirata, Jamie; Cheng, Ji; Ku, Grace; Herrera, Alex F.

doi:10.1182/blood-2019-123449

Cited by 13 publications

(13 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Polatuzumab vedotin (DCDS4501A) is a novel CD79b-directed ADC with site-specific conjugation to MMAE. In 2019, combined polatuzumab vedotin with bendamustine and rituximab was approved by the FDA for patients with r/r DLBCL after at least 2 prior therapies [ 63 ]. Beyond combination with rituximab, the replacement of vincristine with polatuzumab vedotin was tested in a multicenter phase Ib/II study with R-CHP or G (obinutuzumab)-CHP.…”

Section: Monoclonal Antibodies and Antibody–drug Conjugatesmentioning

confidence: 99%

New agents and regimens for diffuse large B cell lymphoma

2020

View full text Add to dashboard Cite

As a widely recognized standard regimen, R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) is able to cure two-thirds patients with diffuse large B cell lymphoma (DLBCL), and the remaining patients suffer from refractory or relapsed disease due to resistance to R-CHOP and fare poorly. Unsatisfied outcomes for those relapsed/refractory patients prompted efforts to discover new treatment approaches for DLBCL, including chimeric antigen receptor T cells, bispecific T cell engagers, immunomodulatory drugs, immune checkpoint inhibitors, monoclonal antibodies, antibody–drug conjugates, molecular pathway inhibitors, and epigenetic-modifying drugs. Herein, up-to-date data about the most promising treatment approaches for DLBCL are recapitulated, and novel genetic classification systems are introduced to guide individualized treatment for DLBCL.

show abstract

Section: Monoclonal Antibodies and Antibody–drug Conjugatesmentioning

confidence: 99%

New agents and regimens for diffuse large B cell lymphoma

2020

View full text Add to dashboard Cite

show abstract

“…The efficacy of pola-BR was recently confirmed in an extended cohort of 106 DLBCL patients. 13 Chimeric antigen receptor (CAR) T-cell therapy has become a promising and potentially curative treatment option for r/r LBCL patients. 14,15 However, a substantial proportion of patients considered eligible for CAR T-cell therapy fails to proceed to dosing because of rapid LBCL progression.…”

Section: Introductionmentioning

confidence: 99%

Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas

et al. 2021

View full text Add to dashboard Cite

The antibody-drug conjugate polatuzumab vedotin (pola) has recently been approved in combination with bendamustine and rituximab (pola-BR) for patients with refractory or relapsed (r/r) large B-cell lymphoma (LBCL). To investigate the efficacy of pola-BR in a real-world setting, we retrospectively analyzed 105 patients with LBCL who were treated in 26 German centers under the national compassionate use program. Fifty-four patients received pola as a salvage treatment and 51 patients were treated with pola with the intention to bridge to chimeric antigen receptor (CAR) T-cell therapy (n = 41) or allogeneic hematopoietic cell transplantation (n = 10). Notably, patients in the salvage and bridging cohort had received a median of 3 prior treatment lines. In the salvage cohort, the best overall response rate was 48.1%. The 6-month progression-free survival and overall survival (OS) was 27.7% and 49.6%, respectively. In the bridging cohort, 51.2% of patients could be successfully bridged with pola to the intended CAR T-cell therapy. The combination of pola bridging and successful CAR T-cell therapy resulted in a 6-month OS of 77.9% calculated from pola initiation. Pola vedotin-rituximab without a chemotherapy backbone demonstrated encouraging overall response rates up to 40%, highlighting both an appropriate alternative for patients unsuitable for chemotherapy and a new treatment option for bridging before leukapheresis in patients intended for CAR T-cell therapy. Furthermore, 7 of 12 patients with previous failure of CAR T-cell therapy responded to a pola-containing regimen. These findings suggest that pola may serve as effective salvage and bridging treatment of r/r LBCL patients.

show abstract

“…Polatuzumab vedotin-piiq is an ADC therapy [60]. It comprises the same linker and payload as in the previous drug (enfortumab vedotin-ejfv), but a different antibody (Figure 9).…”

Section: Polatuzumab Vedotin-piiq (Polivy Tm )mentioning

confidence: 99%

2019 FDA TIDES (Peptides and Oligonucleotides) Harvest

et al. 2020

View full text Add to dashboard Cite

2019 has been an excellent year in terms of peptides and oligonucleotides (TIDES) approved by the FDA. Despite the drop in the number of total drugs approved by the FDA in 2019 in comparison with 2018 (48 vs. 59), the total number of TIDES authorized increased (seven vs. three). Year after year, TIDES are increasingly present in therapy, as imaging agents, theragnostic and constituent moieties of other complex drugs, such as antibody drug conjugates. This means a consolidation of these kinds of drugs in the pharmaceutical arena, paving the way in the coming years for the approval of others for diverse medical indications. Here the TIDES approved in 2019 are analyzed in terms of chemical structure, medical target, mode of action, and adverse effects.

show abstract

Polatuzumab Vedotin Plus Bendamustine with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study

Cited by 13 publications

References 0 publications

New agents and regimens for diffuse large B cell lymphoma

New agents and regimens for diffuse large B cell lymphoma

Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas

2019 FDA TIDES (Peptides and Oligonucleotides) Harvest

Contact Info

Product

Resources

About